Anti-gonadotropin releasing hormone vaccines and their potential use in the treatment of hormone-responsive cancers

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Gonadotropin-releasing hormone (GnRH) and its analogues have been used clinically to treat a range of hormone-dependent conditions. It is often necessary for large, toxic and expensive drug doses to be administered. Improvements in drug delivery have necessitated new developments in formulation, but these in turn can induce new adverse effects. Immunological neutralisation of GnRH has been examined as a less toxic and cheaper replacement therapy, and has been studied closely in different animal species. However, only a few clinical trials have been carried out with respect to hormone-dependent cancers. Based on clinical trials of the free peptide drug in cancer patients, it would appear that there is an increasing trend towards using GnRH and its analogues in adjuvant therapy and that antibody-based GnRH neutralisation will have a role in this treatment regimen.

Original languageEnglish
Pages (from-to)1-12
Number of pages12
JournalBioDrugs
Volume12
Issue number1
DOIs
Publication statusPublished - 31 Jul 1999

Fingerprint

Gonadotropin-Releasing Hormone
Vaccines
Hormones
Poisons
Neoplasms
Clinical Trials
Pharmaceutical Preparations
Therapeutics
Peptides
Antibodies

Keywords

  • gonadotropin release
  • hormone response
  • immunogenicity

Cite this

@article{7530438b5a874d589d6a84d47ba2aeed,
title = "Anti-gonadotropin releasing hormone vaccines and their potential use in the treatment of hormone-responsive cancers",
abstract = "Gonadotropin-releasing hormone (GnRH) and its analogues have been used clinically to treat a range of hormone-dependent conditions. It is often necessary for large, toxic and expensive drug doses to be administered. Improvements in drug delivery have necessitated new developments in formulation, but these in turn can induce new adverse effects. Immunological neutralisation of GnRH has been examined as a less toxic and cheaper replacement therapy, and has been studied closely in different animal species. However, only a few clinical trials have been carried out with respect to hormone-dependent cancers. Based on clinical trials of the free peptide drug in cancer patients, it would appear that there is an increasing trend towards using GnRH and its analogues in adjuvant therapy and that antibody-based GnRH neutralisation will have a role in this treatment regimen.",
keywords = "gonadotropin release, hormone response, immunogenicity",
author = "Ferro, {Valerie A.} and Stimson, {William H.}",
year = "1999",
month = "7",
day = "31",
doi = "10.2165/00063030-199912010-00001",
language = "English",
volume = "12",
pages = "1--12",
journal = "BioDrugs",
issn = "1173-8804",
number = "1",

}

TY - JOUR

T1 - Anti-gonadotropin releasing hormone vaccines and their potential use in the treatment of hormone-responsive cancers

AU - Ferro, Valerie A.

AU - Stimson, William H.

PY - 1999/7/31

Y1 - 1999/7/31

N2 - Gonadotropin-releasing hormone (GnRH) and its analogues have been used clinically to treat a range of hormone-dependent conditions. It is often necessary for large, toxic and expensive drug doses to be administered. Improvements in drug delivery have necessitated new developments in formulation, but these in turn can induce new adverse effects. Immunological neutralisation of GnRH has been examined as a less toxic and cheaper replacement therapy, and has been studied closely in different animal species. However, only a few clinical trials have been carried out with respect to hormone-dependent cancers. Based on clinical trials of the free peptide drug in cancer patients, it would appear that there is an increasing trend towards using GnRH and its analogues in adjuvant therapy and that antibody-based GnRH neutralisation will have a role in this treatment regimen.

AB - Gonadotropin-releasing hormone (GnRH) and its analogues have been used clinically to treat a range of hormone-dependent conditions. It is often necessary for large, toxic and expensive drug doses to be administered. Improvements in drug delivery have necessitated new developments in formulation, but these in turn can induce new adverse effects. Immunological neutralisation of GnRH has been examined as a less toxic and cheaper replacement therapy, and has been studied closely in different animal species. However, only a few clinical trials have been carried out with respect to hormone-dependent cancers. Based on clinical trials of the free peptide drug in cancer patients, it would appear that there is an increasing trend towards using GnRH and its analogues in adjuvant therapy and that antibody-based GnRH neutralisation will have a role in this treatment regimen.

KW - gonadotropin release

KW - hormone response

KW - immunogenicity

U2 - 10.2165/00063030-199912010-00001

DO - 10.2165/00063030-199912010-00001

M3 - Article

VL - 12

SP - 1

EP - 12

JO - BioDrugs

JF - BioDrugs

SN - 1173-8804

IS - 1

ER -